Role Of Nutraceuticals In Cancer Chemosensitization

Role of Nutraceuticals in Chemoresistance to Cancer, Volume Two, focuses on nutraceuticals, the compounds derived from natural sources, which are usually multi-targeted as a means to overcome chemoresistance. This book discusses the role of several compounds related to nutraceuticals and chemoresistance, such as curcumin, resveratrol, indole 3-carbinol, tocotrienols, ursolic acid, fisetin, celastrol, gambogic, butein, catechins and silymarin. It is a valuable resource for cancer researchers, oncologists and members of several areas of the biomedical field who are interested in understanding how to use nutraceuticals as a sensitizing agent for chemotherapy. Brings updated information on natural compounds used as specific inhibitors of cell signaling pathways as reviewed by experts in the field Presents experts analysis and summary of reported and novel findings and potential translational application in cancer patients Describes molecular mechanisms with new and helpful approaches for the readers to use in their own investigations

Dietary supplements and nutraceuticals such as Vitamin A and D, Omega-3 and probiotics are used as part of the cancer treatment as complimenting the main therapy. Several Nutraceuticals have shown to boost the immune responses, while emerging clinical studies and other research suggests that some plant-based agents may, indeed, impact late-stage cancer, influencing molecular processes corrupted by tumor cells to evade detection, expand clonally, and invade surrounding tissues. Advances in Nutraceutical Applications in Cancer: Recent Research Trends and Clinical Applications is an attempt to collect evidence and related clinical information of application of Nutraceuticals to be used in cancer treatment or compliment the cancer treatment. It contains 16 chapters written by experts in related field’s and covers many different aspects of the formulation and development of Nutraceuticals for cancer applications. This book covers efficacy, safety and toxicological aspects of nutraceuticals. It also addresses various novel drug delivery systems of nutraceuticals with anticancer properties, as well as nutraceuticals as supplements for cancer prevention. Features: Offers a comprehensive view of neutraceuticals’ role in cancer prevention and treatment Covers the applications and implications of neutraceuticals in prostate, colorectal, breast and gynecological cancers Discusses the principles of neutrigenomics and neutrigenetics in cancer prevention Explors the role of probiotics and micronutrients in cancer treatment and prevention Nutraceuticals can alter the gut microbiota. Gut microbiome undergoes changes during the disease status and followed by the cancer treatment. Nutraceutical’s role in proliferation and prevention of gynecological cancers, nutraceutical’s role in proliferation and prevention of prostate cancer and role of micronutrients in cancer prevention, both pros and cons, are some of the topics discussed in various chapters in this book. This book is addressed to scientists, clinicians, and students who are working in the area of Nutraceutical applications in cancer treatment.

This book is about Nutraceuticals in cancer therapy, specifically targeted and Adjuvant therapy. It shows several approaches for possibly reducing systemic toxicity. This book illustrates the role of several dietary agents, collectively called nutraceuticals or natural agents in the prevention and/or treatment of human malignancies known to be mediated through alterations in multiple molecular targets. This book contains sixteen chapters which begin with historical perspective on the value of natural agents in the prevention of human malignancies followed by a series of current topics on multiple nutraceuticals targeting multiple cancers. This collection would likely be useful for bringing newer generations with broader perspectives in launching cutting-edge innovative molecular research, which would certainly help in designing targeted clinical trials in order to realize the dream of customize strategies for the prevention and/or treatment of human malignancies without causing any systemic toxicity. Moreover, the knowledge gained would allow novel utilization of nutraceuticals as adjunct to both conventional chemotherapy and radiation therapy in order to improve the overall quality of life and survival of patients diagnosed with cancers.

This unique work compiles the latest knowledge around veterinary nutraceuticals, commonly referred to as dietary supplements, from ingredients to final products in a single source. More than sixty chapters organized in seven sections collate all related aspects of nutraceutical research in animal health and disease, among them many novel topics: common nutraceutical ingredients (Section-I), prebiotics, probiotics, synbiotics, enzymes and antibacterial alternatives (Section-II), applications of nutraceuticals in prevention and treatment of various diseases such as arthritis, periodontitis, diabetes, cognitive dysfunctions, mastitis, wounds, immune disorders, and cancer (Section-III), utilization of nutraceuticals in specific animal species (Section-IV), safety and toxicity evaluation of nutraceuticals and functional foods (Section-V), recent trends in nutraceutical research and product development (Section-VI), as well as regulatory aspects for nutraceuticals (Section-VII). The future of nutraceuticals and functional foods in veterinary medicine seems bright, as novel nutraceuticals will emerge and new uses of old agents will be discovered. International contributors to this book cover a variety of specialties in veterinary medicine, pharmacology, pharmacognosy, toxicology, chemistry, medicinal chemistry, biochemistry, physiology, nutrition, drug development, regulatory frameworks, and the nutraceutical industry. This is a highly informative and carefully presented book, providing scientific insight for academia, veterinarians, governmental and regulatory agencies with an interest in animal nutrition, complementary veterinary medicine, nutraceutical product development and research.

Anti-angiogenic Drugs as Chemosensitizers in Cancer Therapy, Volume 19 focuses on the use of anti-angiogenic drugs as sensitizers of tumor cells to the inhibitory activity of antitumor agents. Conventional and novel anti-neoplastic agents (cytotoxic molecules, hormones/antihormones, immunotherapies) are taken into consideration, along with advances made in combination therapies. The book encompasses examples of studies on the use of antiangiogenic compounds—molecules that inhibit the growth of vessels inside a tumor—together with antineoplastic drugs in order to sensitize the resistant tumor to their cytotoxic effects, thus reducing adverse side reactions and resistance and improving the therapeutic response of cancer patients. In addition, the book discusses clinical applications in various types of cancer, such as colorectal, lung, breast, renal, genitourinary, skin and brain and circulating tumors. It is a valuable resource for cancer researchers, clinicians and members of the biomedical field who wants to be up-to-date on the most recent and promising developments in the field. Provides the most updated reviews on anti-angiogenic drugs as chemosensitizers by leaders in the field Encompasses summarized tables and schematic diagrams in each chapter to give a clear overview on recent findings in a didactic manner Brings not only relevant information of current research but also new ideas and suggestions for further investigations to help advance the field

pH Interfering Agents as Chemosensitizers In Cancer Therapy, Volume Thirteen, provides a detailed overview of the chemosensitizers for the treatment of cancer spanning from biochemical and structural features to pharmacology and drug-design, including technological applications. The book is structured with innovative outlines and a distinction between experimental and clinical results. The continuous discovery and assessment of the role played by old/new synthetic drugs, natural compounds and technological applications has led to the urgent need of classification in terms of biological activity, mechanism of action, clinical outcomes, cancer cell lines sensible to the treatment, and potentialities to better orient research in this field. Moreover, all the aspects relevant for medicinal chemistry (drug design, structure-activity relationships, permeability data, cytotoxicity, appropriate statistical procedures, and molecular modeling studies) are strictly considered. Presents a broad view of the topic according to a medicinal chemistry-based approach beyond syntheses and biological assays, focusing on SAR studies, chemoinformatic, drug targeting and molecular modeling Explains the mechanism of action of the chemosensitizers by means of schemes and figures to facilitate comprehension Discusses novel targets to explore new possibilities that enhance research in the field

Prostate cancer (PCa) is among the most diagnosed cancers in men worldwide as well as one of the most common causes of cancer-related deaths. Despite the advances in treatment, the disease remains associated with poor survival and resistance to cytotoxic and targeted therapies. Therapy Resistance in Prostate Cancer: Mechanisms and Insights highlights the main mechanisms that are responsible for therapy resistance in PCa allowing researchers and clinicians to have a synopsis of current options and new therapies that can be proposed to overcome this resistance. Understanding the mechanisms responsible for chemotherapy resistance helps researchers all over the world to delve deeper into the pathways behind this resistance and potentially discover new therapeutic targets for PCa. Tackles the topic of resistance from a broader perspective, including, but not limited to, the role of the extracellular matrix and cancer stem cells in therapy resistance Creates understanding on how to develop novel therapies that specifically target CSCs to eliminate the regenerating capacity of the tumor and overcome therapy resistance Helps in identifying novel molecular biomarkers and potential therapeutic targets pertaining to the tumor microenvironment to overcome therapy resistance Provides a general view of the main pathways involved in PCa progression that will aid in understanding the mechanisms responsible for chemotherapy resistance

Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment. The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future. This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer. Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response Discusses genetic reversions as a unique alteration and a new field of study Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field